Pacira Biosciences Inc Stock Price, News & Analysis

PACIRA BIOSCIENCES, INC. (NASDAQ: PCRX) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 7:30 AM ET. Investors can access the live audio via the company's website. A replay will be available for two weeks post-event. Pacira is a leader in non-opioid pain management and regenerative health solutions, known for its long-acting local analgesic, EXPAREL®. The company acquired the handheld cryoanalgesia device, iovera⁰, in April 2019 to further its mission of reducing opioid reliance.

Pacira BioSciences (Nasdaq: PCRX) announced preliminary net product sales of $38.1 million for EXPAREL and $0.8 million for iovera° in November 2020, marking a continuation of year-over-year growth despite COVID-19 challenges. The company is optimistic about EXPAREL's increasing adoption in outpatient settings and diverse surgical procedures. However, 2020 sales were affected by pandemic-related elective surgery postponements. The firm will provide ongoing updates on sales for greater transparency as market dynamics evolve post-pandemic.

Pacira BioSciences (NASDAQ: PCRX) will present at the 2020 Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020, at 11:30 AM ET. The live audio can be accessed via the company’s Events page. A replay will be available for two weeks post-event.

Pacira is known for its non-opioid pain management solutions, including EXPAREL®, a long-acting local analgesic launched in April 2012, and the iovera⁰ system acquired in 2019 for targeted nerve treatment.

Pacira BioSciences (NASDAQ: PCRX) announced that the European Commission has granted marketing authorization for EXPAREL for managing post-operative pain in adults. This approval is based on four Phase 3 studies that showed EXPAREL significantly reduces pain and opioid consumption after surgery. The marketing authorization covers all EU member states, the UK, Iceland, Norway, and Liechtenstein, with a launch planned for late 2021. Since its U.S. launch in 2012, EXPAREL has been administered to over 7.5 million patients.

Pacira BioSciences (Nasdaq: PCRX) reported preliminary unaudited net product sales of EXPAREL at $40.7 million and iovera° at $1 million for October 2020. EXPAREL sales grew by 112% year-over-year, marking five consecutive months of growth. Despite challenges from the COVID-19 pandemic affecting elective surgeries, EXPAREL is increasingly used in various surgical procedures. The company plans to continue monthly sales reports to improve transparency regarding COVID-19's impact.

Pacira BioSciences (NASDAQ: PCRX) will present at the 2020 Jefferies Virtual London Healthcare Conference on November 17, 2020, at 2:05 PM GMT (9:05 AM ET). The presentation will be accessible via the company’s events page, with a replay available for two weeks afterward. Pacira is recognized for its commitment to non-opioid pain management solutions, notably through its long-acting local analgesic EXPAREL®, launched in 2012. The company focuses on reducing opioid reliance in healthcare.

Pacira BioSciences (Nasdaq: PCRX) reported a 12% increase in total revenues to $117.5 million for Q3 2020, driven by strong EXPAREL sales, which reached $113.7 million. The net income increased significantly to $130.1 million, aided by a $124.6 million income tax benefit. Operating expenses decreased to $99.9 million, while adjusted EBITDA rose to $34.2 million from $24.8 million a year prior. The company opened a new training facility to enhance pain management practices and reported preliminary September 2020 sales of $39.5 million for EXPAREL. A positive CHMP opinion for EXPAREL was also noted.

Pacira BioSciences, Inc. has launched the Pacira Innovation and Training Center of Tampa (PITT), aimed at enhancing clinician education in non-opioid pain management techniques. The facility features state-of-the-art technology, including ultrasound scanning stations and a large LCD presentation wall. Ongoing workshops will focus on iovera° training, promoting best practices in pain management. Pacira emphasizes the importance of training for improved patient outcomes, reflecting a commitment to shift procedures toward non-opioid solutions. This strategic initiative is expected to contribute to the growing field of regional anesthesia.

Pacira BioSciences, Inc. (NASDAQ:PCRX) will announce its third quarter financial results on October 29, 2020, before U.S. market opening. Following this, a live conference call and webcast will be held at 8:30 a.m. ET. Participants can join by dialing 1-877-845-0779 or 1-720-545-0035 (international), using passcode 5997369. Replay options will be available for one week. Pacira is known for its non-opioid pain management solutions, especially its long-acting analgesic, EXPAREL®, and the iovera⁰ cryoanalgesia device.